Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cowealth Medical Holding Co., Ltd. (4745.TWO)
George Town, KY
Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The company also offers acme empowerment program, including al-assisted clinical decision support system, platform of management analysis and decision making, multi-channel coaxial-time-audio-video-image digital platform for operating rooms, and cross-trait medical resource platform. In addition, it provides equipment comprising CyberKnife Stereotactic Radiosurgery System, a non-invasive treatment alternative for cancerous and non-cancerous tumors, as well as other medical conditions requiring radiation therapy; LipiView Ocular Surface Interferometer and LipiView Thermal Pulsation System, a system designed to diagnose and address meibomian gland dysfunction; and MRIdian-Linac, an MRI-guided radiation therapy system. Further, the company is involved in general investing; import and export medical equipment, reagents, and spare parts; nutrition, health, and social and economic consulting business; software development, IT equipment maintenance, and IT system maintenance service; and hospital and business management. Cowealth Medical Holding Co., Ltd. was founded in 1997 and is based in George Town, Cayman Islands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.25% | -3.93% | -18.67% | -23.56% | -36.02% | -37.28% | -8.62% | -44.01% | -41.22% | -65.78% | -27.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%-29.5% Q1'26: -11.6% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-31,900.0% Q1'26: -2.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.0% Q1'26: -49.4% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-9.3% Q1'26: -7.9% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-5.6% Q1'26: -3.6% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+23.3% Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-3.66× Q1'26: -6.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.27B
est.
|
3.02B
est.
|
3.01B
est.
|
3.91B
est.
|
4.67B
est: 4.72B (-1.2%)
|
4.72B
est: 4.50B (+4.9%)
|
5.14B
est: 5.15B (-0.1%)
|
5.63B
est: 5.66B (-0.6%)
|
| EBITDA |
248.28M
est.
|
228.64M
est.
|
228.56M
est.
|
296.13M
est.
|
527.49M
est: 358.09M (+47.3%)
|
459.12M
est: 341.25M (+34.5%)
|
429.04M
est: 390.17M (+10.0%)
|
470.59M
est: 429.37M (+9.6%)
|
| EBIT |
202.29M
est.
|
186.29M
est.
|
186.23M
est.
|
241.28M
est.
|
429.81M
est: 291.76M (+47.3%)
|
351.10M
est: 278.04M (+26.3%)
|
359.12M
est: 317.90M (+13.0%)
|
413.31M
est: 349.84M (+18.1%)
|
| Net Income |
195.14M
est.
|
166.10M
est.
|
136.37M
est.
|
232.13M
est.
|
279.75M
est: 255.09M (+9.7%)
|
124.39M
est: 203.80M (-39.0%)
|
139.46M
est: 97.50M (+43.0%)
|
94.12M
est: 120.14M (-21.7%)
|
| SGA |
452.44M
est.
|
416.65M
est.
|
416.51M
est.
|
539.64M
est.
|
597.14M
est: 652.54M (-8.5%)
|
617.93M
est: 621.86M (-0.6%)
|
687.62M
est: 711.00M (-3.3%)
|
701.99M
est: 782.44M (-10.3%)
|
| EPS |
3.10
est.
|
2.64
est.
|
2.17
est.
|
3.69
est.
|
3.61
est: 4.06 (-11.0%)
|
1.61
est: 3.24 (-50.3%)
|
1.80
est: 1.55 (+16.1%)
|
1.22
est: 1.91 (-36.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Duane Lee | Founder & Chief Executive Officer | 22.0K | male |
| Jing Tian | Financial Officer & Accounting Officer | — | — |
| Lixuan Lin | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4745.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
